Latest Articles

Publication Date
Glycolytic reprogramming in endometriosis: molecular mechanisms, immune modulation, and non-hormonal therapeutic opportunities.

Endometriosis is a chronic gynecological disorder characterized by ectopic tissue growth and significant morbidity, yet current hormonal and surgical treatments often fail to prevent recurrence or entail severe side effects. …

Published: May 25, 2026, midnight
Identification of the Piperidyl Urea Derivative BAY-439 as a Potent and Selective Inhibitor of Human Phospholipase A2 Group V (hPLA2-G5) for the Treatment of Inflammatory Pain.

Human Phospholipase A2 Group V (hPLA2-G5) is elevated in inflammatory conditions and promotes neutrophil and macrophage recruitment. Its enzymatic activity activates lipid receptors and cytosolic phospholipase A2 (cPLA2), leading to …

Published: May 19, 2026, midnight
Endometrial expression of T-cell immunoreceptor with Ig and ITIM domains and cluster of differentiation 155: A case-control study of a novel immunomodulatory axis in endometriosis.

Endometriosis is a chronic inflammatory disorder affecting about 10% of females in their reproductive years, characterized by endometrial tissue growing outside the uterus. Immune checkpoints play a crucial role in …

Published: May 17, 2026, midnight
Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities.

Angiogenesis mediated by vascular endothelial growth factor A (VEGF-A) is essential for physiological vascular remodeling but also drives pathological processes, including tumor growth, ocular neovascularization, and inflammation. Emerging evidence has …

Published: May 13, 2026, midnight
FGFR2-responsive self-assembled hydrogel releases its inhibitor to suppress the progression of endometriosis.

Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety …

Published: May 9, 2026, midnight
Histone Deacetylase 10 Inhibitors Suppress Progression of Endometriosis via Activation of Interferon Regulatory Factor 6 and Dachshund Homolog 1.

To investigate the mechanisms of histone deacetylase (HDAC) 10 inhibitors (HDAC10Is) action in endometriosis and the target molecules of HDAC10Is.

Published: May 8, 2026, midnight
Targeting the Wnt signaling network in endometriosis: mechanistic insights and translational opportunities.

Endometriosis is a chronic gynecological disorder defined by the growth of endometrial-like tissue outside the uterus, driven by estrogen-dependent inflammation and progressive fibrosis. According to available data, remodeling and persistent …

Published: May 8, 2026, midnight
Targeting TLR4 Attenuates Endometriosis Progression by Suppressing NF-κB/NLRP3 Inflammasome Activation and Angiogenesis.

Endometriosis is a chronic inflammatory disorder affecting approximately 10% of reproductive-age women, yet non-hormonal therapeutic options remain limited. This study investigates the role of the TLR4/NF-κB/NLRP3 inflammasome axis in endometriosis …

Published: May 6, 2026, midnight
miR-769-5p inhibits cellular behaviors associated with endometriosis progression by directly targeting follistatin in vitro.

The pathogenesis of endometriosis (EM) remains intricate and multifactorial. This study aimed to investigate the biological functions of microRNA-769-5p (miR-769-5p) in an in vitro model of EM. Serum was obtained …

Published: April 30, 2026, midnight
Dysregulated endometrial podocalyxin and LIF expression in women with ovarian endometrioma.

To investigate whether ovarian endometrioma is associated with disruption of the endocrine-regulated transition between the anti-adhesive modulator podocalyxin (PCX) and the adhesive modulator leukemia inhibitory factor (LIF) in the endometrium.

Published: April 21, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!